Navigation Links
Patient Disparities Seen in Lung Cancer Drug Trials
Date:7/6/2011

WEDNESDAY, July 6 (HealthDay News) -- Women, older people and minorities are under-represented in lung cancer drug trials in the United States, according to a new study.

Researchers say that this could have a significant impact on the efficacy and safety of new treatments among these groups, particularly the elderly.

"Our results suggest that the trial population used for approval of drugs do not represent well the U.S. population who may receive the marketed agent," the study's principal investigator, Dr. Shakun Malik, a medical officer at the U.S. Food and Drug Administration in Silver Spring, Md., said in a news release.

"This fact is concerning particularly for older patients who may experience greater toxicity when given the same dose and combination of drugs based on testing in a younger population," Malik explained in the release from the International Association for the Study of Lung Cancer.

In conducting the study, which was slated for presentation Wednesday at the 14th World Conference on Lung Cancer in Amsterdam, researchers reviewed 10 years of trial data for the treatment of non-small cell lung cancer submitted to the U.S. Food and Drug Administration.

The study revealed that although 42 percent of patients diagnosed with lung cancer in the United States between 1975 and 2008 were women, only 32 percent of enrollees in 10 national and international drug trials for non-small cell lung cancer between 2000 and 2010 were women.

Moreover, although 73 percent of lung cancer patients in the United States are older than 65, only 36 percent of the drug trial population was in that age group.

Blacks also develop lung cancer at higher rates than whites, but they only comprised 2 percent of trial participants in the 10-year period, the study found. Meanwhile, researchers noted that whites made up 78 percent of enrollees, Asians comprised 15 percent, Hispanics 2 percent and "other" accounted for 2 percent.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute provides more information on lung cancer treatment.

-- Mary Elizabeth Dallas

SOURCE: International Association for the Study of Lung Cancer, news release, July 6, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Elderly Dutch lung patients survival improved by new treatment options between 2003-2009
2. Patients at small, isolated, rural hospitals in US more likely to receive lower quality of care
3. ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
4. Worse outcomes for older breast cancer patients with other health problems
5. Heart transplant patients at risk for serious skin cancers
6. Delaying Intravenous Feeding of ICU Patients May Aid Recovery
7. Research Sheds Light on Cause of Brain Deficits in HIV Patients
8. Patients treated with sunitinib and sorafenib respond to flu vaccine
9. Innovative UBC-BC Cancer Agency system reduces waitlisting for chemotherapy patients
10. Team approach reduces urinary tract infections in rehab patients
11. Intensive, hands-on effort reduces bloodstream infections in critically ill patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patient Disparities Seen in Lung Cancer Drug Trials
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially ... their medication by matching users with high quality water pipes within an ideal price ... commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, who use ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, ... throughout Jasper County and the surrounding region, is initiating a charity drive to assist ... raise funds earmarked for a scholarship fund that will be presented to the chosen ...
(Date:6/23/2016)... , ... June 23, 2016 , ... Representatives of CHA ... the newest member of their staff, Dr. Joshua J. Berger. As of May ... of the world-renowned facility. , Dr. Berger has received recognition for his research, his ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: